In this article

What is ApoB?
Why particles matter more than cargo
ApoB is superior: the evidence
What the 2026 ACC/AHA guideline says
When LDL and ApoB disagree
The triglyceride problem
Understanding your results
Who benefits most?
Why Australian GPs are not there yet
GP vs preventive cardiology
Is it worth it?
Bottom line
Where to from here

○Targeted Testing

ApoB: why 2026 ACC/AHA and NLA guidelines centre it for heart risk

Q: What do the 2026 ACC/AHA cholesterol guidelines say about ApoB?

The 2026 ACC/AHA Guideline on the Management of Dyslipidemia (published 13 March 2026 and co-authored by the National Lipid Association) places ApoB into US clinical practice as a secondary marker for residual risk assessment and treatment guidance. LDL-C remains the primary target. ApoB is specifically recommended when triglycerides are ≥150 mg/dL, in type 2 diabetes, in cardiovascular-kidney-metabolic (CKM) syndrome, when achieved LDL-C is below 70 mg/dL on therapy, or in known cardiovascular disease. The guideline sets numeric ApoB goals that align with LDL targets: <55, <70, or <90 mg/dL by risk category.

Q: What is the difference between ApoB and LDL cholesterol?

LDL-C measures the amount of cholesterol carried in LDL particles. ApoB counts the actual number of atherogenic (plaque-causing) particles in your blood, including LDL, VLDL, IDL, and Lp(a). Since each particle has exactly one ApoB molecule, ApoB gives you a direct particle count. When these markers disagree (10-20% of people), ApoB is the superior predictor of cardiovascular events. The 2026 ACC/AHA guideline incorporates ApoB into US clinical practice for this reason.

Q: What is an optimal ApoB level?

The 2026 ACC/AHA dyslipidemia guideline sets numeric ApoB goals aligned with LDL-C targets: less than 55 mg/dL for very high risk (established cardiovascular disease, recurrent events, multiple risk factors), less than 70 mg/dL for high risk (diabetes, prior ASCVD event, very high calculated risk), and less than 90 mg/dL for intermediate risk. These align with the National Lipid Association 2024 Expert Consensus targets. Australian guidelines do not yet specify ApoB targets, so your health practitioner will interpret results in the context of your overall cardiovascular risk profile.

Q: Is ApoB testing covered by Medicare in Australia?

No, ApoB testing is not currently covered by Medicare in Australia. You will typically pay an out-of-pocket fee when added to a lipid panel. This is one reason most Australian GPs do not routinely order it, they are hesitant to request tests patients must pay for without Medicare support. This is a systemic barrier, not a reflection of the test clinical value. International guidelines including the 2026 ACC/AHA position now formally support its use.

Q: Why is ApoB more accurate when triglycerides are high?

LDL cholesterol is usually calculated using the Friedewald equation, which assumes a fixed ratio between triglycerides and VLDL cholesterol. When triglycerides are elevated (≥150 mg/dL or ≥1.7 mmol/L), this assumption fails and LDL is systematically underestimated. ApoB is directly measured, not calculated, so it remains accurate regardless of triglyceride level. The 2026 ACC/AHA guideline lists triglycerides ≥150 mg/dL as an explicit indication to measure ApoB for exactly this reason.

Q: What are the indications for ApoB testing under the 2026 guideline?

The 2026 ACC/AHA dyslipidemia guideline lists ApoB as appropriate to measure for residual risk and treatment guidance in: triglycerides ≥150 mg/dL, type 2 diabetes, cardiovascular-kidney-metabolic (CKM) syndrome, achieved LDL-C below 70 mg/dL on therapy, and known cardiovascular disease. Family history of early heart disease and metabolic syndrome are additional scenarios where the discordance literature supports testing. Australian guidelines have not yet adopted these indications, so a conversation with your health practitioner (or a preventive cardiologist) is the appropriate next step if you think you may fall into one of these groups.

Q: Can I lower my ApoB?

Yes. The same interventions that lower LDL-C also lower ApoB. Statins are highly effective at reducing ApoB particle count. Dietary changes, especially reducing saturated fat and refined carbohydrates, help. Weight loss can significantly reduce ApoB, particularly if you have metabolic syndrome. Ezetimibe and PCSK9 inhibitors lower ApoB further for those requiring more aggressive treatment. Your health practitioner will determine the appropriate approach based on your risk profile and the 2026 ACC/AHA goal for your risk category.

Q: What is LDL/ApoB discordance?

Discordance means your LDL-C and ApoB tell different stories. For example, you might have normal LDL-C but elevated ApoB, indicating many small, cholesterol-depleted particles representing higher risk than your LDL suggests. About 10-20% of people have discordant results, and when discordant, ApoB is the better predictor. Discordance is particularly common in people with metabolic syndrome, insulin resistance, or elevated triglycerides. The 2026 ACC/AHA guideline includes ApoB in part to surface this residual risk.

Q: How is ApoB testing accessed in Australia?

Common pathways include: (1) asking your GP to add ApoB to a lipid panel request, with the cost paid out-of-pocket; (2) seeing a preventive cardiologist or other specialist who incorporates ApoB into advanced lipid assessment; or (3) ordering through a direct-to-consumer pathology service. Any NATA-accredited pathology laboratory can run the test. The barrier in Australia is typically awareness and Medicare coverage rather than availability.

The 2026 ACC/AHA dyslipidemia guideline (co-authored by the National Lipid Association) gave ApoB an official seat in the heart-risk algorithm. With 10-20% of people having "normal" LDL but elevated particle numbers, this is the test that catches the risk cholesterol misses.

10 min read·13 June 2026

9 of 9

studies show ApoB outperforms LDL cholesterol for predicting cardiovascular events

Source: [1]

The Short Answer

Yes for the specific clinical scenarios outlined in the 2026 ACC/AHA guideline. The 2026 ACC/AHA/NLA dyslipidemia guideline (published March 2026, replacing the 2018 cholesterol guideline) formally placed ApoB into US clinical practice as a risk-assessment and treatment-guidance target. LDL-C remains the primary target, but ApoB is now recommended for people with triglycerides ≥150 mg/dL, type 2 diabetes, cardiovascular-kidney-metabolic (CKM) syndrome, achieved LDL-C below 70 mg/dL, or known cardiovascular disease. Numeric ApoB goals align with LDL targets: <55, <70, or <90 mg/dL by risk category. ApoB directly counts every atherogenic particle in your blood, whilst LDL-C only estimates cholesterol content. In 10-20% of people the two markers disagree, and when they do, ApoB is the better predictor. Australian guidelines have not yet caught up, so Medicare does not cover it and most GPs are not familiar with the new targets.^[1][5][11]

What Is ApoB?

Apolipoprotein B (ApoB) is a protein on the surface of every atherogenic (plaque-causing) particle in your blood. This includes LDL, VLDL, IDL, and Lp(a), all the lipoproteins that contribute to cardiovascular disease.^[2]

The critical insight: there is exactly one ApoB molecule per particle. Measuring ApoB gives you a direct count of all particles capable of building arterial plaque.

LDL cholesterol measures cargo, how much cholesterol the particles are carrying. ApoB counts vehicles, how many particles are on the road. And it is the number of vehicles, not the cargo, that determines risk.^[1]

Why Particles Matter More Than Cargo

The Highway Analogy

Your bloodstream is a highway. Cholesterol travels in vehicles called lipoproteins.

LDL-C measures cargo (total cholesterol on the road)
ApoB counts vehicles (how many trucks are making deliveries)

Two people with identical LDL-C can have vastly different particle counts:

Person A: 1,000 large particles, each heavily loaded with cholesterol
Person B: 2,000 small particles, each carrying less cholesterol

Same total cargo. Twice the traffic. Person B has double the cardiovascular risk.^[2]

More particles means more opportunities for those particles to penetrate artery walls and form plaque. This is why particle number is the superior predictor.

ApoB Is Superior: The Evidence

The evidence is no longer debatable. ApoB outperforms LDL cholesterol in every major study:

LDL Cholesterol (LDL-C)

Measures cholesterol content only
Usually estimated via calculation
Inaccurate when triglycerides >1.7 mmol/L
Misses VLDL, IDL, and Lp(a) contribution
Primary target under the 2026 ACC/AHA guideline^[11]
Medicare-covered in Australia

ApoB

Counts all atherogenic particles directly
Superior predictor in 9 of 9 studies^[1]
Directly measured (not calculated)
Accurate at any triglyceride level
Captures LDL + VLDL + IDL + Lp(a)
Recommended for risk assessment + treatment guidance (2026 ACC/AHA)^[11]
Not Medicare-covered

What the 2026 ACC/AHA Guideline Says About ApoB

The Guideline Shift (March 2026)

On 13 March 2026, the American College of Cardiology, the American Heart Association, and nine other societies including the National Lipid Association (NLA) published the new Guideline on the Management of Dyslipidemia. It retires the 2018 cholesterol guideline and formally incorporates ApoB into US clinical practice.^[11]

Key positions on ApoB:

LDL-C remains the primary target of lipid-lowering therapy
ApoB is recommended as a secondary marker for residual risk assessment and treatment guidance
Use ApoB once LDL-C and non-HDL-C goals are met, particularly when residual risk is suspected

Indications to measure ApoB:

Triglycerides ≥ 150 mg/dL (≥1.7 mmol/L)
Type 2 diabetes
Cardiovascular-kidney-metabolic (CKM) syndrome
Achieved LDL-C below 70 mg/dL on therapy (assess residual risk)
Known cardiovascular disease

The NLA being a co-author matters: the NLA had already issued an Expert Clinical Consensus in 2024 endorsing ApoB superiority for risk assessment.^[5] The 2026 joint guideline brings the US mainstream in line with that position.

Numeric ApoB Goals (2026 ACC/AHA)

The 2026 guideline sets numeric ApoB goals that mirror LDL-C targets:^[11]

Very high risk: ApoB < 55 mg/dL
High risk: ApoB < 70 mg/dL
Intermediate risk: ApoB < 90 mg/dL

These align with the National Lipid Association 2024 Expert Consensus targets.^[5] Australian guidelines do not yet specify ApoB targets, so your health practitioner will interpret results in the context of your overall cardiovascular risk profile.

International Guideline Picture

United States (2026): ACC/AHA/NLA joint guideline now incorporates ApoB for risk assessment and treatment guidance.^[11]

Europe (2025 update): ESC/EAS guidelines prioritise ApoB, particularly in patients with elevated triglycerides, diabetes, or metabolic syndrome.^[1]

National Lipid Association (2024): "ApoB has been shown to be superior to LDL-C in risk assessment both before and during treatment with lipid-lowering therapy."^[5]

Australia (2023): The Heart Foundation guideline still focuses on LDL-C. ApoB targets are not specified. Updated guidance is anticipated but has not yet been released.^[6]

When LDL and ApoB Disagree

10-20% Have Discordant Results

In approximately 10-20% of people, LDL-C and ApoB tell different stories:^[3]

"Normal" LDL but elevated ApoB: Many small, cholesterol-depleted particles. Higher risk than LDL suggests.
Elevated LDL but normal ApoB: Fewer, larger particles carrying more cholesterol each. Lower risk than LDL suggests.

A 2025 UK Biobank study of 41,099 participants found that even at just 2% discordance, cardiovascular risk was already elevated. At 30% discordance, hazard ratios reached 2.5x for coronary artery disease.^[4]

When discordant, ApoB is the better predictor. This is why the 2026 ACC/AHA guideline includes ApoB as a residual-risk tool and why European guidelines now favour it as the preferred marker.^[1][11]

The Triglyceride Problem

LDL Is Usually Calculated, And Often Wrong

LDL cholesterol is rarely measured directly. It is usually calculated using the Friedewald equation from your total cholesterol, HDL, and triglycerides.

The problem is that the calculation assumes a fixed ratio that breaks down when triglycerides are elevated:^[7]

Triglycerides 1.7-2.3 mmol/L: LDL underestimated by ~9 mg/dL
Triglycerides 2.3-4.5 mmol/L: LDL underestimated by ~18 mg/dL
Triglycerides >4.5 mmol/L: Calculation unreliable

"The Friedewald equation tends to underestimate LDL-C most when accuracy is most crucial," notes Johns Hopkins researcher Dr Seth Martin. Patients with high triglycerides may receive falsely reassuring "normal" LDL results whilst their actual risk is elevated.^[7]

ApoB is directly measured, no calculation, no assumptions, no triglyceride interference. This is precisely why the 2026 ACC/AHA guideline lists triglycerides ≥150 mg/dL as an explicit indication to add ApoB.^[11]

Understanding Your Results

ApoB is reported in mg/dL or g/L. The 2026 ACC/AHA goals, aligned with NLA 2024 targets and ESC/EAS thresholds, are below.^[1][5][11]

Below 55 mg/dL (0.55 g/L)Optimal for very high risk

2026 ACC/AHA target for very high risk: established cardiovascular disease, multiple major risk factors, or recurrent events. Associated with the lowest residual event rates.

55-69 mg/dL (0.55-0.7 g/L)Target for high risk

2026 ACC/AHA target for high-risk individuals (diabetes, prior ASCVD event, very high calculated risk). Many preventive cardiologists aim here proactively.

70-89 mg/dL (0.7-0.9 g/L)Target for intermediate risk

2026 ACC/AHA target for intermediate-risk individuals. Reasonable goal for those without major risk factors but with family history or borderline markers.

90-99 mg/dL (0.9-1.0 g/L)Above intermediate-risk goal

Above the intermediate-risk ApoB goal. Discuss with your health practitioner, particularly if other risk factors are present.

100-119 mg/dL (1.0-1.2 g/L)Borderline elevated

Higher than optimal across all risk strata. Management options should be discussed.

120+ mg/dL (1.2+ g/L)Elevated

Associated with increased cardiovascular risk. Your health practitioner will discuss treatment options including lifestyle, statins, ezetimibe, or PCSK9 inhibitors.

Who Benefits Most?

ApoB testing provides superior risk assessment for everyone, but the 2026 ACC/AHA guideline names specific groups where it offers the greatest yield:^[11]

Risk Factor	Why It Matters
	Explicit 2026 ACC/AHA indication. Friedewald equation underestimates LDL-C, ApoB provides accurate particle count regardless of triglyceride level.^[11]
	Explicit 2026 ACC/AHA indication. Diabetic dyslipidaemia features small, dense LDL where LDL-C is most misleading.^[11]
	Explicit 2026 ACC/AHA indication for residual-risk assessment. ApoB reveals whether particle number is still elevated despite low cholesterol.^[11]
	Explicit 2026 ACC/AHA indication. Helps target very high risk goal (<55 mg/dL).^[11]
	Especially if family members had events with normal cholesterol. May indicate inherited particle phenotype that LDL-C misses.
	Small, dense LDL particles common. ApoB often elevated despite normal LDL-C. Discordance highly common.

Why Australian GPs Are Not There Yet

Local Guidelines Lag

The 2023 Heart Foundation CVD risk guideline focuses on LDL-C. ApoB targets are not specified. The 2026 ACC/AHA, 2025 ESC/EAS, and 2024 NLA positions have not yet been mirrored in Australia.

No Medicare Rebate

ApoB testing is not covered by Medicare in Australia. Patients pay out-of-pocket. GPs are understandably hesitant to order tests patients must pay for.

Education Gap

Most Australian GPs trained on LDL-C targets. ApoB was not part of their education, and many are not yet familiar with the 2026 ACC/AHA goals or indications.

Workflow Inertia

LDL-C pathways are established with Medicare coverage and familiar management protocols. Shifting to ApoB-inclusive management requires both guideline update and rebate change in Australia.

GP vs Preventive Cardiology Perspectives

Standard Australian GP Approach

Focus on LDL-C as primary target
Use Australian CVD risk calculator (Aus CVD Risk)
Treat if absolute risk exceeds threshold
Generally not yet familiar with ApoB targets
Follow 2023 Heart Foundation / RACGP guidelines

Preventive Cardiology / 2026-Aligned Care

LDL-C primary, ApoB for residual risk and treatment guidance
Use 2026 ACC/AHA numeric ApoB goals (<55 / <70 / <90 mg/dL)
Earlier treatment thresholds reflecting lifetime risk
Advanced testing: Lp(a), particle size, hs-CRP
Follow 2026 ACC/AHA, 2025 ESC/EAS, 2024 NLA guidance

Neither approach is wrong, they reflect different philosophies about prevention. Standard GP care follows current Australian guidelines. Preventive cardiology adopts international evidence more rapidly. Your choice depends on your risk tolerance and how proactively you want to manage cardiovascular health.

Access in Australia

Advanced lipid markers including ApoB, Lp(a), and hs-CRP are increasingly available in Australia through preventive cardiology services and direct-to-consumer pathology providers. Real-world cohort data suggest that a substantial proportion of people with standard cholesterol in target ranges still have ApoB above current international goals.^[8] The 2026 ACC/AHA dyslipidemia guideline reflects this evidence becoming part of mainstream international practice.^[11]

Is It Worth It?

✗ Probably Skip If...

Standard lipid testing is enough for your needs and you trust LDL-C alone
Cost is a significant consideration (not Medicare-covered)
Your health practitioner has advised against adding ApoB in your situation
You prefer to follow current Australian guidelines only

✓ Worth Considering If...

Triglycerides ≥150 mg/dL (an explicit 2026 ACC/AHA indication)^[11]
Type 2 diabetes or cardiovascular-kidney-metabolic syndrome (2026 ACC/AHA indication)^[11]
Already on therapy with achieved LDL-C below 70 mg/dL and want to check residual risk^[11]
Known cardiovascular disease and aiming for the <55 mg/dL very-high-risk goal^[11]
Family history of early heart disease, especially with normal cholesterol
Working with a preventive cardiologist or functional medicine practitioner

The Bottom Line

The 2026 ACC/AHA dyslipidemia guideline incorporates ApoB into US clinical practice. Co-authored by the National Lipid Association, it places ApoB into US clinical pathways as a residual-risk and treatment-guidance target, with defined indications and numeric goals aligned to LDL targets (<55, <70, <90 mg/dL).^[11]

LDL-C remains the primary target. ApoB is the marker that captures information LDL-C does not, particularly in the 10-20% of people where the two disagree.^[3] European guidelines prioritise ApoB further.^[1] The NLA Expert Consensus describes it as superior for risk assessment both before and during treatment.^[5]

The current gap in Australia is implementation, not evidence:

Medicare does not currently cover ApoB testing (out-of-pocket)
Australian guidelines have not yet adopted the 2026 ACC/AHA positions
Many Australian GPs are not yet familiar with the new targets
Patients in scope for the 2026 indications may need to raise the topic with their health practitioner or work with a preventive cardiologist

This article is for general education. Decisions about testing and treatment should be made with your health practitioner in the context of your individual risk profile.

Where to from here

If you would like your ApoB tested, Clarity Labs offers it as part of our Heart Health panel and as an individual add-on. If not, we hope this gave you something evidence-based to discuss with your regular doctor.

Frequently Asked Questions